Andreas Kuhn | Vice President
BioNTech Ag

Andreas Kuhn, Vice President, BioNTech Ag

Andreas Kuhn has worked in the field of RNA biochemistry and molecular biology for more than thirty years. His work on RNA-based immunotherapies began in 2007 in the academic group of Ugur Sahin at the University Clinic Mainz, and Andreas joined BioNTech RNA Pharmaceuticals GmbH shortly after its founding in 2008. In his current role as Senior Vice President RNA Biochemistry & Manufacturing the main focus is expanding proprietary technologies to increase the efficacy of RNA-based therapies and to optimize GMP-compatible manufacturing processes for RNA. He has co-authored numerous publications and patents ranging from basic research on RNA to its application as a diagnostic and therapeutic agent.


Day 2, April 8 @ 09:40

Interactive panel: Unique rapid production opportunities and challenges that face RNA delivery and manufacture

  • Why and where will it make a difference?
  • How is it difference to DNA vaccines?
  • What are the unique challenges and advantages of RNA vaccine?
  • How will RNA vaccines help in an outbreak like corona? Can the scale-up/volume be big enough?
  • Advantages of RNA are clearly from the speed and applicability to ID and cancer, but does the speed have any affect on the overall quality of the vaccine?
last published: 05/Mar/20 10:35 GMT

back to speakers

Sign Up for Event Updates